News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synta Pharmaceuticals (SNTA) Provides Clinical Updates and Reports Third Quarter 2013 Financial Results


11/4/2013 6:39:37 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided clinical updates and reported financial results for the third quarter ended September 30, 2013.

The GALAXY program in lung cancer

At the 2013 World Conference on Lung Cancer (WCLC) last month, investigators presented one year follow-up results from the ongoing GALAXY-1 trial, evaluating Synta’s lead oncology drug candidate, ganetespib, in combination with docetaxel (G+D) vs. docetaxel (D) alone for the second-line treatment of advanced non-small cell lung cancer (NSCLC).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES